AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26138292 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 induction of Bcl-3 expression in CD4+ T cells
Number of subjects: 0
Study 26138292 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome analysis of Bcl-3-transduced CD4+ T cells
Number of subjects: 0
Study 24476350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk-reduction intervention
Number of subjects: 738
Study 24476350 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 738
Study 21846536 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX II in AP group
Number of subjects: 27
Study 21846536 — intervention group
Group type: EXPERIMENTAL
Intervention: Root ZX II in VT group
Number of subjects: 27
Study 21846536 — intervention group
Group type: COMPARATOR
Intervention: Comparison between AP and VT groups
Number of subjects: 27
Study 20307823 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized yoga plus standard care
Number of subjects: 54
Study 20307823 — intervention group
Group type: COMPARATOR
Intervention: Standard care (No Yoga)
Number of subjects: 54
Study 20307823 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized yoga treatment
Number of subjects: 54
Study 17991119 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 33
Study 17991119 — intervention group
Group type: COMPARATOR
Intervention: Control group (gonadotrophins)
Number of subjects: 33
Study 14768920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound online imaging during epidural puncture
Number of subjects: 30
Study 14768920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound offline scan technique
Number of subjects: 30
Study 14768920 — intervention group
Group type: COMPARATOR
Intervention: Conventional combined spinal‐epidural anaesthesia (Control)
Number of subjects: 30
Study 12153648 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth center care
Number of subjects: 1063
Study 12153648 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1063
Study 11475743 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SMI)
Number of subjects: 16
Study 11475743 — intervention group
Group type: COMPARATOR
Intervention: Potassium magnesium aspartate
Number of subjects: 16
Study 7647944 — intervention group
Group type: COMPARATOR
Intervention: Educational paragraph describing CPR and its outcomes (read to half of respondents)
Number of subjects: 661
Study 7647944 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of or experience with Alzheimer's disease
Number of subjects: 661
Study 7647944 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 661
Study 7647944 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater income
Number of subjects: 661
Study 7647944 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 661
Study 7647944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwhite race
Number of subjects: 661
Study 2475915 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 37
Study 2475915 — intervention group
Group type: COMPARATOR
Intervention: Laser + high-dose-rate Iridium 192 afterloading therapy
Number of subjects: 37
Study 1031798 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin injection tests (HOLLANDER criterion)
Number of subjects: 74
Study 1031798 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin injection tests (BACHRACH criterion)
Number of subjects: 74
Study 1031798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride test
Number of subjects: 74
Study 30877216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg + csDMARD
Number of subjects: 0
Study 30877216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg + csDMARD
Number of subjects: 0
Study 30877216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 0
Study 30877216 — intervention group
Group type: COMPARATOR
Intervention: Placebo + csDMARD
Number of subjects: 0
Study 30877216 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA) 40 mg
Number of subjects: 0
Study 28727704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% with dexamethasone 8 mg
Number of subjects: 82
Study 28727704 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% with saline (control)
Number of subjects: 82
Study 25954828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation
Number of subjects: 186
Study 25954828 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 186
Study 25954828 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser plus acidulated phosphate fluoride (APF)
Number of subjects: 186
Study 25954828 — intervention group
Group type: COMPARATOR
Intervention: Control group (negative control)
Number of subjects: 186
Study 23450028 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedicular balloon kyphoplasty
Number of subjects: 44
Study 23450028 — intervention group
Group type: COMPARATOR
Intervention: Bipedicular balloon kyphoplasty
Number of subjects: 44
Study 21320829 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based neuroanatomical localization application
Number of subjects: 39
Study 21320829 — intervention group
Group type: COMPARATOR
Intervention: Standard textbook resources (control group)
Number of subjects: 39
Study 19850252 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI with Proxis Embolic Protection System
Number of subjects: 284
Study 19850252 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI alone (Control)
Number of subjects: 284
Study 19850252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 284
Study 16840382 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist nurse follow-up
Number of subjects: 154
Study 16840382 — intervention group
Group type: COMPARATOR
Intervention: Respiratory doctor follow-up
Number of subjects: 154
Study 14509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-antibiotic prescriptions (co-prescriptions)
Number of subjects: 5469
Study 14509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prescriptions
Number of subjects: 5469
Study 14509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucomodifiers, steroidal anti-inflammatory drugs, and bronchodilators
Number of subjects: 5469
Study 14509552 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs and antitussives
Number of subjects: 5469
Study 10839226 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh protectors
Number of subjects: 2
Study 10839226 — intervention group
Group type: COMPARATOR
Intervention: Control (no thigh protectors)
Number of subjects: 2
Study 9177364 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 36
Study 9177364 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36
Study 8463521 — intervention group
Group type: EXPERIMENTAL
Intervention: L-deprenyl
Number of subjects: 39
Study 8463521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3544661 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (MH) prophylaxis, 1 g three times daily
Number of subjects: 109
Study 3544661 — intervention group
Group type: COMPARATOR
Intervention: No MH prophylaxis
Number of subjects: 109
Study 29864418 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual sexual stimuli (AVSS) during the follicular phase
Number of subjects: 22
Study 29864418 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual sexual stimuli (AVSS) during the luteal phase
Number of subjects: 22
Study 29864418 — intervention group
Group type: EXPERIMENTAL
Intervention: First exposure to AVSS during luteal phase
Number of subjects: 22
Study 29873467 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Proseal™ (LMA-P)
Number of subjects: 180
Study 29873467 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 180
Study 29873467 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme™ (LMA-S)
Number of subjects: 180
Study 23989910 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous injection of flomoxef (group 1)
Number of subjects: 279
Study 23989910 — intervention group
Group type: COMPARATOR
Intervention: Multiple doses of flomoxef (five additional doses after surgery, group 2)
Number of subjects: 279
Study 21957982 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile block (0.25% bupivacaine, 0.5 mg·kg(‐1))
Number of subjects: 54
Study 21957982 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural (0.25% bupivacaine, 0.5 ml·kg(‐1))
Number of subjects: 54
Study 20049951 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine (6-MP) at 30 mg/day for 12 weeks
Number of subjects: 257
Study 20049951 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-MP at 15-80 mg/day based on RBC 6-TGN, WBC count, and body weight
Number of subjects: 257
Study 20049951 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular measurement of RBC 6-TGN
Number of subjects: 257
Study 18720362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 375
Study 16253102 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 32
Study 16253102 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable membrane
Number of subjects: 32
Study 12381079 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs (captopril and enalapril)
Number of subjects: 119
Study 12381079 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 119
Study 12381079 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 119
Study 12381079 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 119
Study 10195551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and N2O from a rebreathing bag (Sevo/Bag)
Number of subjects: 80
Study 10195551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% and N2O 60% from a circle system (Sevo/Circle)
Number of subjects: 80
Study 10195551 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg/kg as an i.v. bolus
Number of subjects: 80
Study 10195551 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental sodium 5 mg/kg as an i.v. bolus
Number of subjects: 80
Study 8665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosulide 25 mg b.d.
Number of subjects: 8
Study 8665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosulide (both doses)
Number of subjects: 8
Study 8665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosulide (repeated treatment)
Number of subjects: 8
Study 1983629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate statistical methods applied to clinical databank or registry data
Number of subjects: 0
Study 7437274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lysine salicylate 1.8 g (corresponding to acetylsalicylic acid (ASA) 1.0 g)
Number of subjects: 17
Study 7437274 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone 1.0 g
Number of subjects: 17
Study 7437274 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lysine salicylate (ASA)
Number of subjects: 17
Study 30758170 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise on sea sand (SS group)
Number of subjects: 22
Study 30758170 — intervention group
Group type: COMPARATOR
Intervention: Self-management (SM group)
Number of subjects: 22
Study 30223235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (n=46)
Number of subjects: 140
Study 30223235 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor with passive interventions (n=48)
Number of subjects: 140
Study 30223235 — intervention group
Group type: COMPARATOR
Intervention: Active self-exercise (Control group, n=46)
Number of subjects: 140
Study 26626794 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated vaginal dinoprostone (group A, n = 47)
Number of subjects: 94
Study 26626794 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (group B, n = 47)
Number of subjects: 94
Study 24105610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg twice daily for 4 weeks)
Number of subjects: 25
Study 24105610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24105610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 25
Study 21831254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse and dentifrice with 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 0
Study 21831254 — intervention group
Group type: COMPARATOR
Intervention: Negative control regimen (minus active ingredients dentifrice and mouth rinse)
Number of subjects: 0
Study 21831254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 0
Study 20577130 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP added to conventional treatment (n = 38)
Number of subjects: 96
Study 20577130 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP > 5.8 h
Number of subjects: 96
Study 20577130 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP group
Number of subjects: 96
Study 20577130 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (n = 37)
Number of subjects: 96
Study 17434094 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-potassium-insulin (GKI) infusions
Number of subjects: 933
Study 17434094 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 933
Study 16315822 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected carotid artery stenting (PCAS)
Number of subjects: 1
Study 16315822 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1
Study 12173194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 12)
Number of subjects: 24
Study 12173194 — intervention group
Group type: COMPARATOR
Intervention: Propofol (n = 12)
Number of subjects: 24
Study 10634567 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity screening and complete eye examination by a pediatric ophthalmologist
Number of subjects: 6292
Study 10634567 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic cataracts noted in children
Number of subjects: 6292
Study 10634567 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-trauma surgery care
Number of subjects: 6292
Study 8944090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipragoside 0.5% aqueous ophthalmic gel, administered four times a day for 2 weeks after a week of placebo treatment
Number of subjects: 24
Study 8944090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8944090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipragoside 0.5% aqueous ophthalmic gel
Number of subjects: 24
Study 1684653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.25 micrograms/kg
Number of subjects: 5
Study 1684653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 0.50 micrograms/kg
Number of subjects: 5
Study 1684653 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 1.0 micrograms/kg
Number of subjects: 5
Study 1684653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (FEN) 2 micrograms/kg
Number of subjects: 5
Study 1684653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 7120379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortner scale
Number of subjects: 0
Study 7120379 — intervention group
Group type: EXPERIMENTAL
Intervention: Jenkins Activity Survey (JAS)
Number of subjects: 0
Study 7120379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandler Hazary Questionnaire and Eysenck Personality Inventory (SHEPI)
Number of subjects: 0
Study 7120379 — intervention group
Group type: COMPARATOR
Intervention: Social variables
Number of subjects: 0
Study 31547944 — intervention group
Group type: EXPERIMENTAL
Intervention: D90 >101%
Number of subjects: 266
Study 31547944 — intervention group
Group type: COMPARATOR
Intervention: D90 <101%
Number of subjects: 266
Study 28017907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) delivered via phone calls for 8 weeks
Number of subjects: 50
Study 28017907 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 50
Study 28017907 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 50
Study 27931252 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertising patient and public involvement (PPIR) using a leaflet and invitations to potential participants.
Number of subjects: 8182
Study 27931252 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advertising of PPIR).
Number of subjects: 8182
Study 27931252 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertising PPIR using a leaflet and invitations to potential participants.
Number of subjects: 8182
Study 24919195 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose protocol (100 kVp tube voltage, 100 mAs tube current, 3.2 pitch, sinogram affirmed iterative reconstruction)
Number of subjects: 42
Study 24919195 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (120 kVp tube voltage, 120 mAs tube current, 2.4 pitch, filtered back projection)
Number of subjects: 42
Study 23324248 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE plus best medical treatment (BMT)
Number of subjects: 28
Study 23324248 — intervention group
Group type: COMPARATOR
Intervention: BMT alone
Number of subjects: 28
Study 23324248 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE plus BMT
Number of subjects: 28
Study 19925464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Basiliximab (Tac/Bas)
Number of subjects: 451
Study 19925464 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus/MMF (Tac/MMF)
Number of subjects: 451
Study 19925464 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus/MMF/steroids (Control)
Number of subjects: 451
Study 17884451 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/d for 12 weeks
Number of subjects: 46
Study 17884451 — intervention group
Group type: COMPARATOR
Intervention: Untreated diabetic patients with CAD
Number of subjects: 46
Study 15716847 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique using an operating microscope and minimal osteotomy
Number of subjects: 66
Study 15716847 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique without an operating microscope
Number of subjects: 66
Study 12059812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotization of the varicocele
Number of subjects: 67
Study 12059812 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 67
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron mesylate intravenous infusion
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg dolasetron mesylate intravenous infusion
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron mesylate intravenous infusion
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron mesylate oral administration
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodolasetron (active metabolite)
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodolasetron
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron and hydrodolasetron
Number of subjects: 24
Study 10086835 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 24
Study 8589617 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic isolated limb perfusion with melphalan
Number of subjects: 181
Study 8589617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperthermic isolated limb perfusion with melphalan
Number of subjects: 181
Study 8589617 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac isolation level during ILP
Number of subjects: 181
Study 2188202 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis-component diphtheria and tetanus toxoids and pertussis vaccine (DTP)
Number of subjects: 7
Study 2188202 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed DTP vaccine
Number of subjects: 7
Study 2188202 — intervention group
Group type: COMPARATOR
Intervention: Acellular pertussis component DTP vaccine
Number of subjects: 7
Study 2188202 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine (in infants)
Number of subjects: 7
Study 2188202 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine (in 4- to 6-year-old children)
Number of subjects: 7
Study 7066739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 25 mg
Number of subjects: 0
Study 7066739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ephedrine 50 mg
Number of subjects: 0
Study 7066739 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular saline (placebo)
Number of subjects: 0
Study 31340979 — intervention group
Group type: EXPERIMENTAL
Intervention: Two infusions of 1-g rituximab at 2-week intervals (NICE cohort)
Number of subjects: 55
Study 31340979 — intervention group
Group type: COMPARATOR
Intervention: Two infusions of 375 mg/m2 at 1-week intervals (GEMRITUX cohort)
Number of subjects: 55
Study 31340979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined study population
Number of subjects: 55
Study 27235666 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplement >185 mg/day
Number of subjects: 409
Study 27235666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DHA supplement)
Number of subjects: 409
Study 25820612 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month paliperidone palmitate (175, 263, 350, or 525 mg eq)
Number of subjects: 506
Study 25820612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 23800342 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 456
Study 23800342 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 456
Study 21063203 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 28